Get the Daily Brief
Latest Biotech News
Harbour Biomed, Lannacheng tie up on radionuclide‑drug conjugates
Harbour Biomed and Yantai Lannacheng Biotechnology announced a long‑term strategic collaboration to co‑develop next‑generation radionuclide‑drug conjugates for oncology. The partners said the deal...
In vivo gene therapy momentum... editing tools still racing to catch up
Two pieces this week captured the state of gene‑based medicine: a review noting 2025 as a breakout year for in vivo gene therapies and an industry dispatch on the proliferation of gene‑editing...
Thousands of lytic phages uncovered: virulent phages show persistence
Large‑scale genomic surveys revealed thousands of previously unknown lytic bacteriophages embedded in bacterial genomes, while complementary work found virulent phages capable of long‑term...
New preclinical oncology agents: GAS41 YEATS inhibitor and selective BTK blockers
Researchers disclosed a first‑in‑class GAS41 (YEATS4) inhibitor for non‑small‑cell lung cancer and published selective Bruton tyrosine kinase (BTK) inhibitors that block invasion and progression...
Late-stage bone drug fails: Ultragenyx, Mereo see stocks tumble
Ultragenyx Pharmaceutical and partner Mereo BioPharma announced the categorical failure of their late-stage candidate for a rare bone disease in a pivotal trial. The companies disclosed the...
Genmab pulls plug on lung bispecific... BioNTech had already walked
Genmab announced it will terminate clinical development of acasunlimab, a bispecific antibody previously co-developed with BioNTech. The decision follows BioNTech’s exit from the asset last year...
FDA clears Diasorin molecular POC: Four‑plex test wins 510(k) and CLIA waiver
The US Food and Drug Administration granted 510(k) clearance and a CLIA waiver to Diasorin’s Liaison Nes platform and its four-plex molecular assay for Flu A/B, RSV and SARS‑CoV‑2. Diasorin said...
Harbour Biomed inks radionuclide conjugate pact with Lannacheng
Harbour Biomed and Yantai Lannacheng Biotechnology signed a long-term strategic collaboration to advance next-generation radionuclide–drug conjugates (RDCs) for cancer treatment. The partners will...
Adlai Nortye licenses pan‑RAS oral AN‑9025 to Ask Pharm
Adlai Nortye Ltd. granted an exclusive license to Jiangsu Aosaikang Pharmaceutical (Ask Pharm) for AN‑9025, an oral pan‑RAS(ON) inhibitor designed to target a broad spectrum of activating RAS...
First‑in‑class GAS41 YEATS inhibitor unveiled for NSCLC
Researchers disclosed a first‑in‑class inhibitor targeting GAS41, the YEATS4‑encoded chromatin reader frequently overexpressed in non‑small‑cell lung cancer (NSCLC). Preclinical data presented...
New BTK inhibitors curb GBM invasion – selectivity solves ibrutinib's limits
Researchers reported novel Bruton tyrosine kinase (BTK) inhibitors that block invasion and progression in glioblastoma (GBM) models while offering improved selectivity relative to ibrutinib. The...
Plasma protein profile flags cancer in symptomatic patients
A recent study unveiled a plasma protein profiling approach capable of predicting cancer in patients presenting with non‑specific symptoms. The minimally invasive test integrates multiplexed...
Potent cross‑neutralizing antibodies neutralize Marburg and Ravn viruses
Scientists discovered a class of potent antibodies that cross‑neutralize Marburg virus and the related Ravn virus, according to a report in npj Viruses. The antibodies show broad neutralizing...
PCMT1 linked to new degron pathway on cereblon substrates
Biochemists reported that protein carboxymethyltransferase 1 (PCMT1) generates a C‑terminal degron on substrates of cereblon (CRBN), the E3 ligase adapter central to the activity of...
Diasorin wins FDA OK: 15‑minute molecular POC cleared
The US Food and Drug Administration issued 510(k) clearance and a CLIA waiver for Diasorin’s LIAISON Nes four‑plex molecular assay, enabling detection of influenza A/B, RSV and SARS‑CoV‑2 at the...
Plasma protein panel spots cancer in symptomatic patients
Researchers published a plasma protein profiling study showing a blood‑based panel can predict cancer in patients presenting with non‑specific symptoms. The lead finding: a multiplex protein...
Meta‑analysis: CAR‑T and bispecifics split outcomes in indolent B‑cell NHL
A new meta‑analysis compared chimeric antigen receptor T‑cell (CAR‑T) therapy with bispecific antibody treatments for relapsed or refractory indolent B‑cell non‑Hodgkin’s lymphomas. The pooled...
Researchers find cross‑neutralizing antibodies vs Marburg and Ravn
Scientists reported discovery of potent cross‑neutralizing human antibodies that neutralize Marburg virus and the related Ravn virus, according to a paper in npj Viruses. The antibodies target...
Senhwa pushes CX‑5461 into combo play with ADC and PD‑1 tie‑up
Senhwa Biosciences announced a clinical collaboration with BeOne Medicines to evaluate CX‑5461 in combination with an antibody‑drug conjugate (ADC) and BeOne’s marketed PD‑1 inhibitor, targeting...
Genetic screening in oncology... adoption lags despite safety gains
A MedCity News report reviewed emerging genetic screening tools that predict rare but deadly adverse reactions to common cancer drugs and improve drug selection. Despite mounting evidence of...